Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. - Wikidata - awgldk - TriplyDB

Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial.

Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial.

http://www.wikidata.org/entity/Q34576644

about

Critical limb ischemia: advanced medical therapy Defining risks and predicting adverse events after lower extremity bypass for critical limb ischemia Antithrombotic treatment for peripheral arterial disease Surgeon, not institution, case volume is associated with limb outcomes after lower extremity bypass for critical limb ischemia in the Vascular Quality Initiative.Acute reductions in mechanical wall strain precede the formation of intimal hyperplasia in a murine model of arterial occlusive disease.Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease.Infrainguinal open reconstruction: a review of surgical considerations and expected outcomes.Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications Critical limb ischemia Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia.Disparities in vascular surgery: is it biology or environment?Is atherectomy the best first-line therapy for limb salvage in patients with critical limb ischemia?Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss.Prediction of graft patency and mortality after distal revascularization and interval ligation for hemodialysis access-related hand ischemia.Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia Mouse vein graft hemodynamic manipulations to enhance experimental utility Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?Evidence for the Use of Multiple Mechanisms by Herpes Simplex Virus-1 R7020 to Inhibit Intimal Hyperplasia.Influence of risk factors and comorbidities on the successful therapy and survival of patients with critical limb ischemia Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population.The role of established and emerging risk factors in peripheral vascular graft occlusion.Evidence-based guide to perioperative medicine.Impact of critical limb ischemia on long-term cardiac mortality in diabetic patients undergoing percutaneous coronary revascularization.Prior contralateral amputation predicts worse outcomes for lower extremity bypasses performed in the intact limb Critical limb ischemia: medical and surgical management.Decrease in total aneurysm-related deaths in the era of endovascular aneurysm repair.Using risk models to improve patient selection for high-risk vascular surgery.The burden of peripheral artery disease and the role of antiplatelet therapy.Statin therapy--Part II: Clinical considerations for cardiovascular disease.Vein graft failure: from pathophysiology to clinical outcomes.Results for primary bypass versus primary angioplasty/stent for lower extremity chronic limb-threatening ischemia.Haemodynamic optimisation in lower limb arterial surgery: room for improvement?The impact of preoperative statin therapy on open and endovascular abdominal aortic aneurysm repair outcomes.APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia.Trends and outcomes after surgical lower limb revascularization in England.Lower extremity bypass for critical limb ischemia decreases major adverse limb events with equivalent cardiac risk compared with endovascular intervention.Statins Have a Dose-Dependent Effect on Amputation and Survival in Peripheral Artery Disease Patients.Imaging stem cell therapy for the treatment of peripheral arterial disease.Quality of care among patients undergoing lower extremity revascularization.

P2860

Q26995245-711BA5D1-32AB-42DF-A78F-2B1CF5F85A5F Q27024684-375A94F6-700D-45D9-ABCF-57904E05DFD1 Q28200650-C69219A6-61D8-45A9-A94E-3CBA0A78019B Q30252310-97870613-F50C-43F3-AE5E-56C297E78D2D Q30399953-C38716AE-3DE9-43E8-A47C-327FA1B86B83 Q33462060-C8DDC5CA-8F47-437D-BC6B-5628C80AB200 Q33674067-9BF90138-4C90-42FD-A53F-0D70571E3436 Q33712421-AFB2F529-197E-407C-941F-218E079B2855 Q33814176-9DEEDBEC-2A43-4480-95B8-6C67FEDACD6E Q33932475-A16D0051-4A9A-422F-AF91-198909298F8D Q33957240-C5A9750B-5220-427E-9588-FA891DA77243 Q33962534-0E8E4A8D-9F65-495C-BD0C-4BC77631FFF0 Q33983869-F7C8FDAC-0FF0-46D6-98B3-0494060F6709 Q34055676-6969961E-46BC-4B87-AE49-D41C43B89A08 Q34089672-85914D97-6166-4220-9A93-C1E76A62FB6F Q35071270-37CA4F81-8359-4CE7-9F87-BA35B917D8B0 Q35216396-CBC1450B-55FB-44F1-8B79-2502956BED5E Q35680074-135C9E14-CE81-44C4-87D7-168D8200B5E4 Q35714144-9872ED83-26CD-4696-90D9-86346461EDC0 Q35820827-920AEB63-4BB5-47C7-80DE-35691608267B Q36808026-3A3B9ED4-0915-4B94-B143-C294E3C29B21 Q36834437-36227882-09E4-4AB8-88BB-31F3BAB3A42B Q36868203-7D5C3649-C807-4F35-B228-1957088238FE Q37155172-6E2BA1A3-D315-4A3A-B3B2-82F56CB6A813 Q37238150-D7E00C9B-628E-4D95-BCBE-85A0F05ABF52 Q37258261-16216EFD-BAEF-4AF0-9F4D-27FEE5E52416 Q37288327-4B9758AF-6EB5-4996-94B5-2153722FEE53 Q37566082-AC802C94-FA38-4F0D-9E44-DD5A309F4BE3 Q37765064-2C260AEB-24CC-4EB6-83B8-73460F43770D Q38837879-1A1B0B86-8498-4AA6-958E-05A3489FDCB2 Q40301490-5E4A9F30-2D43-43F2-8ED8-517C71DBCF8D Q42666084-9A65EF10-6F71-4C7C-8492-AF77C711C364 Q42688278-0C46D2EB-C4A2-4F6A-86FC-495906099854 Q43843460-A29DF92F-D1FF-4DAB-A59F-3C6898C3B064 Q44023711-F94DF79F-BFDC-467F-9D37-ECB045BE8373 Q45062210-D4993469-1CDB-47B4-AD27-0D2682758B1E Q47564054-FECA3382-2C45-40CF-B753-655ABE8A97BA Q50666246-59789B73-A0C2-4F49-ADB2-2D988FFEF6FE Q51114226-6E5B4215-ED49-42A6-89C1-AAA4894D21FC

P2860

Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial.

http://www.wikidata.org/entity/Q34576644

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@ast

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@en

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@nl

type

label

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@ast

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@en

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@nl

prefLabel

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@ast

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@en

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@nl

P1433

Q34576644-30464A53-3749-4407-A0BF-6EA2619F54A7

P1476

Q34576644-5EB5D156-4FEB-4082-972C-BB8DA97C1797

P2093

Q34576644-184FE5B3-ECA8-4F6F-BC50-87F30ECEE879

Q34576644-3817BAC1-00A0-45E3-AA7E-E573F026FECE

Q34576644-3DF657E4-6C25-4778-B334-E840A307AAAA

Q34576644-D3B30EC0-F782-4457-ABF2-2311D45CBA56

Q34576644-ED7215CD-A459-4CCA-BC19-6AE94EE548F1

Q34576644-FB11792D-38D5-4AD0-82A5-5E5BE1954FA6

P2860

Q34576644-01DCE88E-ECAF-4E92-879B-922FC1A0C3EF

Q34576644-0D635388-2B4F-40A7-B7C1-E33B1EF1626E

Q34576644-1BE63CB9-97D1-46D8-8D6C-4C302F8C245E

Q34576644-2A20B8A0-DFE9-410F-B477-64A4ECC51A33

Q34576644-31C18627-9DDD-44F1-AA53-D619758B2493

Q34576644-347CD02C-9C4F-4BB4-8844-673C5DD47773

Q34576644-3F1B99F0-6BBD-4FF7-9D73-B492D7311503

Q34576644-4C7B3A5B-D054-4768-A6A1-4D46FDF70BEF

Q34576644-5A349BBE-1CE4-4556-972C-420199508B39

Q34576644-63F4DCA0-26BF-4FB2-9434-A50D55E81607

P304

Q34576644-0B31D649-6A58-46C1-AFA0-A4D616225882

P31

Q34576644-C1647FE0-0AB3-4EFA-98F3-BF9DFCFA882A

P356

Q34576644-12CF3C6E-3619-466C-968A-B889553E2F45

P433

Q34576644-74F28BF1-4310-4D1D-ADFD-7BCC02BC5278

P478

Q34576644-C3DE1BFF-0CF9-425A-8E81-C78909887A9C

P577

Q34576644-DBEAFBE0-201B-4C03-9921-25551F219EC5

P5875

Q34576644-3FB97740-08BC-4DC7-A776-15FF84E4468F

P698

Q34576644-AD9C61B0-55C7-4DB6-9A28-226626E4D842

P921

Q34576644-9FD82BD2-FB1B-4150-B93A-F83294D58D79

P932

Q34576644-3E1BD5F8-BF1A-43EA-BB43-446D2F15EC7B

P356

J.JVS.2005.05.001

P1433

Journal of Vascular Surgery

P1476

Risk factors, medical therapie ...... PREVENT III multicenter trial.

@en

P2093

Alexander W Clowes

http://www.w3.org/2001/XMLSchema#string

Dennis F Bandyk

http://www.w3.org/2001/XMLSchema#string

Gregory L Moneta

http://www.w3.org/2001/XMLSchema#string

Hamid Namini

http://www.w3.org/2001/XMLSchema#string

Lynn Seely

http://www.w3.org/2001/XMLSchema#string

Michael S Conte

http://www.w3.org/2001/XMLSchema#string

P2860

Pleiotropic effects of statins

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Peripheral arterial disease detection, awareness, and treatment in primary care

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization.

Continued adverse trends in coronary heart disease mortality among blacks, 1980-91.

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

P304

456-64; discussion 464-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JVS.2005.05.001

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7591395

http://www.w3.org/2001/XMLSchema#string

P698

16171587

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

1451244

http://www.w3.org/2001/XMLSchema#string